Contact: Frank H. Kerrigon Director - Corporate Communications 
Telephone: 1-800-544-4624, ext. 325
Email: fkerrigon@ezem.com 

E-Z-EM APPOINTS BRAD S. SCHRECK AS SENIOR VICE PRESIDENT - GLOBAL MARKETING 

Westbury, New York; June 5, 2002 - E-Z-EM, Inc., (AMEX: EZM.A and EZM.B) today announced that 
it has appointed Brad S. Schreck to the position of Senior Vice President - Global Marketing. 
Mr. Schreck's responsibilities will cover the Company's Diagnostic Products Division and will 
include Virtual Colonoscopy products, CT contrast injectors, contrast media and related 
medical devices, and immunoassay tests. 

Commenting on the appointment, Anthony A. Lombardo, President and CEO of E-Z-EM, said, "We are 
very pleased to have Brad Schreck join the E-Z-EM senior management team. Brad brings to E-Z-EM 
a wide range of experiences in the healthcare industry, with strong emphasis on marketing, 
strategic planning and product development processes. His responsibilities will include moving 
the Company into new areas within our radiology framework of expertise, while growing our 
existing worldwide franchise in imaging products, especially in the CT arena."

Mr. Schreck previously held senior marketing positions at Pfizer/Howmedica, C.R. Bard, Tyco 
Healthcare, ACMI Circon and Fairchild Medical Systems. He holds a Bachelor of Science degree 
in Organic Chemistry and a Master of Engineering degree in Biomedical Engineering from Stevens 
Institute of Technology and a Master of Business Administration degree in Marketing from 
Fairleigh Dickinson University. Mr. Schreck lives in Totowa, New Jersey, with his wife and 
three children. About E-Z-EM, Inc.

About E-Z-EM, Inc. 
E-Z-EM, the world's largest manufacturer of contrast agents for gastrointestinal radiology, 
has developed the only CT injector on the market that can help detect contrast extravasation, 
the new EmpowerCTTM) with patented EDA(TM) technology. The Company has also recently introduced 
a complete tool kit for virtual colonoscopy (also referred to as CT colonography, or CTC), an 
innovative technology that could lead to a substantial increase in the number of patients being 
screened for colorectal cancer. Virtual colonoscopy visualizes the gastrointestinal tract using 
advanced CT imaging and 3D computer reconstruction of that data. The Company's product line 
consists of the InnerviewGI(TM) 3D imaging workstation; LoSo Prep(TM) and NutraPrep(TM) 
patient-friendly colon preparation products and nutritional meal kits; a tagging agent 
trade-named Tagitol(TM) to help practitioners distinguish pathology from colonic residue; and 
the PROTOCO2L(TM) carbon dioxide colon insufflation system. E-Z-EM's wholly owned subsidiary, 
AngioDynamics, manufactures a wide range of products, including angiographic, vascular access, 
thrombolytic, angioplasty, stents, as well as abdominal infection drainage products. 
AngioDynamics' focus is on diagnostic and therapeutic products for interventional radiology 
and other areas of minimally invasive surgery. Enteric Products, Inc., another subsidiary, 
develops, manufactures and markets tests for detection of the ulcer- and cancer-causing 
bacterium Helicobacter pylori. For additional information, please contact Frank Kerrigon at 
1-800-544-4624, ext. 325, (E-mail: fkerrigon@ezem.com) or visit our corporate web site at 
www.ezem.com. 

The statements made in this document contain certain forward-looking statements that involve a 
number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", 
"believes", "seeks", "estimates," or variations of such words and similar expressions, are 
intended to identify such forward-looking statements. Investors are cautioned that actual 
events or results may differ from the Company's expectations. In addition to the matters 
described above, the ability of the Company to develop its products, future actions by the 
FDA or other regulatory agencies, results of pending or future clinical trials, overall 
economic conditions, general market conditions, foreign currency exchange rate fluctuations, 
the effects on pricing from Group Purchasing Organizations, competition, including alternative 
procedures which continue to replace traditional fluoroscopic procedures, as well as the risk 
factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited 
to its Form 10-Q for the quarter ended March 2, 2002, as well as its Annual Report on Form 
10-K for the year ended June 2, 2001, may affect the actual results achieved by the Company. . 

End